Tabernine B



Compound IDCDAMM02200
Common nameTabernine B
IUPAC name3,9-dimethyl-4,8,10-triazatetracyclo[8.6.1.05,17.011,16]heptadeca-1(17),2,4,11,13,15-hexaene
Molecular formulaC16H17N3

Experimental data

Retention time8.55
Adduct[M+K]+
Actual mz290.105
Theoretical mz290.105
Error0.83
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.324

Identifiers and class information

Inchi keyZDRMIRKEMZHLHE-UHFFFAOYNA-N
SmilesN=1C(=CC=2C=3C=CC=CC3N4C2C1CCNC4C)C
SuperclassOrganoheterocyclic compounds
ClassIndoles and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)0
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)1
Molecular weight (mol_MW)251.33
Computed dipole moment(dipole)2.226
Total solvent accessible surface area (SASA)547.627
Hydrophobic component of SASA (FOSA)268.137
Hydrophilic component of SASA (FISA)54.895
Pie component of the SASA (PISA)224.595
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)907.496
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)2.5
Free energy of solvation of dipole (dip^2/V)0.0054584
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0045651
Globularity descriptor (glob)0.82777
Predicted polarizability in cubic angstroms (QPpolrz)32.309
Predicted hexadecane/gas partition coefficient (QPlogPC16)8.714
Predicted octanol/gas partition coefficient (QPlogPoct)13.054
Predicted water/gas partition coefficient (QPlogPw)6.865
Predicted octanol/water partition coefficient (QPlogPo/w)3.257
Predicted aqueous solubility (QPlogS)-4.121
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.825
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.116
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)745.127
Predicted brain/blood partition coefficient (QPlogBB)0.428
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)398.222
Predicted skin permeability, log Kp (QPlogKp)-3.803
PM3 calculated ionization potential (IP(ev))8.212
PM3 calculated electron affinity (EA(eV))0.477
Number of likely metabolic reactions (#metab)2
Prediction of binding to human serum albumin (QPlogKhsa)0.597
Predicted qualitative human oral absorption (HumanOralAbsorption)3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)100
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)26.424
Number of nitrogen and oxygen atoms (#NandO)3
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction
P08912CHRM5Muscarinic acetylcholine receptor M5T79961SwissTargetPrediction
P11229CHRM1Muscarinic acetylcholine receptor M1T28893SwissTargetPrediction
P36544CHRNA7Neuronal acetylcholine receptor protein alpha-7 subunitT34429SwissTargetPrediction
P29475NOS1Nitric-oxide synthase, brainT16117SwissTargetPrediction
P35228NOS2Nitric oxide synthase, inducibleT02703SwissTargetPrediction
Q16853AOC3Amine oxidase, copper containingT69619SwissTargetPrediction
P15144ANPEPAminopeptidase NT67272SwissTargetPrediction
P27487DPP4Dipeptidyl peptidase IVT31391SwissTargetPrediction
P34913EPHX2Epoxide hydrataseT35734SwissTargetPrediction
O60341KDM1ALysine-specific histone demethylase 1T16739SwissTargetPrediction
P32297CHRNA3Neuronal acetylcholine receptor; alpha3/beta4T74166SwissTargetPrediction
P07101THTyrosine 3-hydroxylaseT62390SwissTargetPrediction
P51681CCR5C-C chemokine receptor type 5T09960SwissTargetPrediction
Q9H3N8HRH4Histamine H4 receptorT26500SwissTargetPrediction
P25021HRH2Histamine H2 receptorT30985SwissTargetPrediction
P14902IDO1Indoleamine 2,3-dioxygenaseT89697SwissTargetPrediction
P28845HSD11B111-beta-hydroxysteroid dehydrogenase 1T65200SwissTargetPrediction
P25100ADRA1DAlpha-1d adrenergic receptorT53381SwissTargetPrediction
P52732KIF11Kinesin-like protein 1T28484SwissTargetPrediction
Q9H2K2TNKS2Tankyrase-2T38087SwissTargetPrediction
P37231PPARGPeroxisome proliferator-activated receptor gammaT58921SwissTargetPrediction
Q9UHL4DPP7Dipeptidyl peptidase IIT50773SwissTargetPrediction
O75116ROCK2Rho-associated protein kinase 2T06093SwissTargetPrediction
Q12884FAPFibroblast activation protein alpha (by homology)T53764SwissTargetPrediction
P52333JAK3Tyrosine-protein kinase JAK3T23172SwissTargetPrediction
P29597TYK2Tyrosine-protein kinase TYK2T78932SwissTargetPrediction
Q9NWZ3IRAK4Interleukin-1 receptor-associated kinase 4T55398SwissTargetPrediction
P41146OPRL1Nociceptin receptorT52921SwissTargetPrediction
P46098HTR3ASerotonin 3a (5-HT3a) receptorT64591SwissTargetPrediction
Q6V1X1DPP8Dipeptidyl peptidase VIIIT15855SwissTargetPrediction
Q86TI2DPP9Dipeptidyl peptidase IXT66252SwissTargetPrediction
Q96JM7L3MBTL3Lethal(3)malignant brain tumor-like protein 3T33931SwissTargetPrediction
P41180CASRCalcium sensing receptorT92076SwissTargetPrediction
Q8WTV0SCARB1Scavenger receptor class B member 1 (by homology)T62998SEA
P30939HTR1FSerotonin 1f (5-HT1f) receptorT78656SwissTargetPrediction
Q9NR97TLR8Toll-like receptor 8T48703SwissTargetPrediction
Q13224GRIN2BGlutamate [NMDA] receptor subunit epsilon 2T76414SwissTargetPrediction
P53634CTSCDipeptidyl peptidase IT70490SwissTargetPrediction
P35499SCN4ASodium channel protein type IV alpha subunitT02546SwissTargetPrediction
P19801AOC1Diamine oxidaseT77546SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
T79961DI0002Abnormal micturition[ICD-11: MF50]P08912CHRM5
T79961DI0032Anterior uveitis[ICD-11: 9A96]P08912CHRM5
T79961DI0034Appearance/behaviour symptom[ICD-11: MB23]P08912CHRM5
T79961DI0037Asthma[ICD-11: CA23]P08912CHRM5
T79961DI0061Brain disease[ICD-11: 8C70-8E61]P08912CHRM5
T79961DI0071Central and peripheral nervous disease[ICD-11: 8A04-8E7Z]P08912CHRM5
T79961DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P08912CHRM5
T79961DI0093Cognition symptoms/signs/clinical symptom[ICD-11: MB21]P08912CHRM5
T79961DI0105Cough[ICD-11: MD12]P08912CHRM5
T79961DI0124Digestive system disease[ICD-11: DE2Z]P08912CHRM5
T79961DI0145Female pelvic pain[ICD-11: GA34]P08912CHRM5
T79961DI0154Functional bladder disorder[ICD-11: GC50]P08912CHRM5
T79961DI0158Gastritis[ICD-11: DA42]P08912CHRM5
T79961DI0162General examination[ICD-11: QA00]P08912CHRM5
T79961DI0166Glaucoma[ICD-11: 9C61]P08912CHRM5
T79961DI0190Hypertension[ICD-11: BA00-BA04]P08912CHRM5
T79961DI0208Infectious gastroenteritis/colitis[ICD-11: 1A40]P08912CHRM5
T79961DI0218Irritable bowel syndrome[ICD-11: DD91]P08912CHRM5
T79961DI0307Nystagmus[ICD-11: 9C84]P08912CHRM5
T79961DI0315Oesophagus motility disorder[ICD-11: DA21]P08912CHRM5
T79961DI0324Pain[ICD-11: MG30-MG3Z]P08912CHRM5
T79961DI0329Pancreatitis[ICD-11: DC31-DC34]P08912CHRM5
T79961DI0331Parkinsonism[ICD-11: 8A00]P08912CHRM5
T79961DI0333Peptic ulcer[ICD-11: DA61]P08912CHRM5
T79961DI0338Polyuria[ICD-11: MF55]P08912CHRM5
T79961DI0411Tonus and reflex abnormality[ICD-11: MB47]P08912CHRM5
T79961DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P08912CHRM5
T79961DI0424Urgency[ICD-11: N.A.]P08912CHRM5
T28893DI0001Abdominal pelvic pain[ICD-11: MD81]P11229CHRM1
T28893DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11229CHRM1
T28893DI0101Corneal disease[ICD-11: 9A76-9A78]P11229CHRM1
T28893DI0129Dystonic disorder[ICD-11: 8A02]P11229CHRM1
T28893DI0154Functional bladder disorder[ICD-11: GC50]P11229CHRM1
T28893DI0157Gastric ulcer[ICD-11: DA60]P11229CHRM1
T28893DI0166Glaucoma[ICD-11: 9C61]P11229CHRM1
T28893DI0186Hyperhidrosis[ICD-11: EE00]P11229CHRM1
T28893DI0218Irritable bowel syndrome[ICD-11: DD91]P11229CHRM1
T28893DI0331Parkinsonism[ICD-11: 8A00]P11229CHRM1
T28893DI0333Peptic ulcer[ICD-11: DA61]P11229CHRM1
T28893DI0371Sebaceous gland disorder[ICD-11: ED91]P11229CHRM1
T34429DI0101Corneal disease[ICD-11: 9A76-9A78]P36544CHRNA7
T34429DI0370Schizophrenia[ICD-11: 6A20]P36544CHRNA7
T16117DI0173Headache[ICD-11: 8A80-8A84]P29475NOS1
T16117DI0264Migraine[ICD-11: 8A80]P29475NOS1
T02703DI0083Chronic kidney disease[ICD-11: GB61]P35228NOS2
T02703DI0320Osteoarthritis[ICD-11: FA00-FA05]P35228NOS2
T02703DI0375Sepsis[ICD-11: 1G40-1G41]P35228NOS2
T02703DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P35228NOS2
T69619DI0190Hypertension[ICD-11: BA00-BA04]Q16853AOC3
T67272DI0351Psoriasis[ICD-11: EA90]P15144ANPEP
T31391DI0009Acute diabete complication[ICD-11: 5A2Y]P27487DPP4
T31391DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P27487DPP4
T35734DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P34913EPHX2
T35734DI0190Hypertension[ICD-11: BA00-BA04]P34913EPHX2
T16739DI0012Acute myeloid leukaemia[ICD-11: 2A60]O60341KDM1A
T16739DI0025Alzheimer disease[ICD-11: 8A20]O60341KDM1A
T16739DI0138Ewing sarcoma[ICD-11: 2B52]O60341KDM1A
T16739DI0238Lung cancer[ICD-11: 2C25]O60341KDM1A
T16739DI0241Lymphoma[ICD-11: 2A80-2A86]O60341KDM1A
T16739DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]O60341KDM1A
T16739DI0284Myelodysplastic syndrome[ICD-11: 2A37]O60341KDM1A
T16739DI0286Myeloproliferative neoplasm[ICD-11: 2A20]O60341KDM1A
T16739DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]O60341KDM1A
T74166DI0105Cough[ICD-11: MD12]P32297CHRNA3
T62390DI0019Adrenomedullary hyperfunction[ICD-11: 5A75]P07101TH
T62390DI0306Nutritional deficiency[ICD-11: 5B50-5B71]P07101TH
T09960DI0184Human immunodeficiency virus disease[ICD-11: 1C60-1C62]P51681CCR5
T26500DI0037Asthma[ICD-11: CA23]Q9H3N8HRH4
T26500DI0039Atopic eczema[ICD-11: EA80]Q9H3N8HRH4
T26500DI0351Psoriasis[ICD-11: EA90]Q9H3N8HRH4
T26500DI0366Rheumatoid arthritis[ICD-11: FA20]Q9H3N8HRH4
T26500DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q9H3N8HRH4
T30985DI0161Gastro-oesophageal reflux disease[ICD-11: DA22]P25021HRH2
T30985DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P25021HRH2
T30985DI0333Peptic ulcer[ICD-11: DA61]P25021HRH2
T89697DI0117Depression[ICD-11: 6A70-6A7Z]P14902IDO1
T65200DI0210Influenza[ICD-11: 1E30-1E32]P28845HSD11B1
T65200DI0239Lupus erythematosus[ICD-11: 4A40]P28845HSD11B1
T65200DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P28845HSD11B1
T53381DI0166Glaucoma[ICD-11: 9C61]P25100ADRA1D
T53381DI0175Heart failure[ICD-11: BD10-BD1Z]P25100ADRA1D
T53381DI0190Hypertension[ICD-11: BA00-BA04]P25100ADRA1D
T53381DI0348Prostate hyperplasia[ICD-11: GA90]P25100ADRA1D
T53381DI0378Sexual dysfunction[ICD-11: HA00-HA01]P25100ADRA1D
T53381DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P25100ADRA1D
T28484DI0012Acute myeloid leukaemia[ICD-11: 2A60]P52732KIF11
T28484DI0172Head and neck cancer[ICD-11: 2D42]P52732KIF11
T28484DI0241Lymphoma[ICD-11: 2A80-2A86]P52732KIF11
T28484DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P52732KIF11
T28484DI0274Multiple myeloma[ICD-11: 2A83]P52732KIF11
T28484DI0321Ovarian cancer[ICD-11: 2C73]P52732KIF11
T28484DI0361Renal cell carcinoma[ICD-11: 2C90]P52732KIF11
T28484DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P52732KIF11
T38087DI0321Ovarian cancer[ICD-11: 2C73]Q9H2K2TNKS2
T58921DI0009Acute diabete complication[ICD-11: 5A2Y]P37231PPARG
T58921DI0025Alzheimer disease[ICD-11: 8A20]P37231PPARG
T58921DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P37231PPARG
T06093DI0168Graft-versus-host disease[ICD-11: 4B24]O75116ROCK2
T53764DI0300Neutropenia[ICD-11: 4B00]Q12884FAP
T23172DI0023Alopecia[ICD-11: ED70]P52333JAK3
T23172DI0039Atopic eczema[ICD-11: EA80]P52333JAK3
T23172DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P52333JAK3
T23172DI0366Rheumatoid arthritis[ICD-11: FA20]P52333JAK3
T78932DI0351Psoriasis[ICD-11: EA90]P29597TYK2
T55398DI0039Atopic eczema[ICD-11: EA80]Q9NWZ3IRAK4
T55398DI0109Cutaneous lupus erythematosus[ICD-11: EB50-EB5Z]Q9NWZ3IRAK4
T55398DI0241Lymphoma[ICD-11: 2A80-2A86]Q9NWZ3IRAK4
T55398DI0339Postoperative inflammation[ICD-11: 1A00-CA43]Q9NWZ3IRAK4
T55398DI0351Psoriasis[ICD-11: EA90]Q9NWZ3IRAK4
T55398DI0366Rheumatoid arthritis[ICD-11: FA20]Q9NWZ3IRAK4
T52921DI0039Atopic eczema[ICD-11: EA80]P41146OPRL1
T52921DI0117Depression[ICD-11: 6A70-6A7Z]P41146OPRL1
T52921DI0173Headache[ICD-11: 8A80-8A84]P41146OPRL1
T52921DI0175Heart failure[ICD-11: BD10-BD1Z]P41146OPRL1
T64591DI0087Chronic pain[ICD-11: MG30]P46098HTR3A
T64591DI0101Corneal disease[ICD-11: 9A76-9A78]P46098HTR3A
T64591DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P46098HTR3A
T64591DI0218Irritable bowel syndrome[ICD-11: DD91]P46098HTR3A
T64591DI0293Nausea/vomiting[ICD-11: MD90]P46098HTR3A
T15855DI0300Neutropenia[ICD-11: 4B00]Q6V1X1DPP8
T66252DI0300Neutropenia[ICD-11: 4B00]Q86TI2DPP9
T92076DI0189Hyper-parathyroidism[ICD-11: 5A51]P41180CASR
T78656DI0264Migraine[ICD-11: 8A80]P30939HTR1F
T78656DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P30939HTR1F
T48703DI0133Epidermal dysplasias[ICD-11: EK90]Q9NR97TLR8
T48703DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]Q9NR97TLR8
T48703DI0180Herpes simplex infection[ICD-11: 1F00]Q9NR97TLR8
T48703DI0239Lupus erythematosus[ICD-11: 4A40]Q9NR97TLR8
T48703DI0252Melanoma[ICD-11: 2C30]Q9NR97TLR8
T48703DI0283Mycosis fungoides[ICD-11: 2B01]Q9NR97TLR8
T48703DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9NR97TLR8
T48703DI0393Squamous cell carcinoma[ICD-11: 2B60-2D01]Q9NR97TLR8
T48703DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q9NR97TLR8
T76414DI0024Alpha-1-antitrypsin deficiency[ICD-11: 5C5A]Q13224GRIN2B
T70490DI0064Bronchiectasis[ICD-11: CA24]P53634CTSC
T02546DI0281Musculoskeletal disorder[ICD-11: FA00-FC0Z]P35499SCN4A

Copyright © 2025